Current Report Filing (8-k)
February 09 2015 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2015
MannKind Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-50865 |
|
13-3607736 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
28903 North Avenue Paine
Valencia, California |
|
91355 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (661) 775-5300
N/A
(Former name or
former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c)) |
As previously announced by us and Sanofi in a joint press release on
February 3, 2015, AFREZZA® is now available by prescription in United States retail pharmacies. AFREZZA, our only approved product, is a rapid-acting inhaled insulin that was approved by
the U.S. Food and Drug Administration on June 27, 2014 to improve glycemic control in adult patients with diabetes.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
MANNKIND CORPORATION |
|
|
|
|
Dated: February 9, 2015 |
|
|
|
By: |
|
/s/ David Thomson |
|
|
|
|
|
|
Name: |
|
David Thomson, Ph.D., J.D. |
|
|
|
|
|
|
Title: |
|
Corporate Vice President, General Counsel and Secretary |
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024